Oncopeptides (Sweden) Probability of Future Stock Price Finishing Under 0.02
| ONCO Stock | SEK 1.50 0.02 1.32% |
Oncopeptides |
Oncopeptides Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Oncopeptides for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Oncopeptides AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Oncopeptides AB may become a speculative penny stock | |
| Oncopeptides AB had very high historical volatility over the last 90 days | |
| Oncopeptides AB has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 118.3 M. Net Loss for the year was (1.43 B) with profit before overhead, payroll, taxes, and interest of 74.16 M. | |
| Oncopeptides AB has accumulated about 747.47 M in cash with (1.52 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Oncopeptides Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Oncopeptides Stock often depends not only on the future outlook of the current and potential Oncopeptides' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oncopeptides' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 75.3 M | |
| Cash And Short Term Investments | 362.2 M |
Oncopeptides Technical Analysis
Oncopeptides' future price can be derived by breaking down and analyzing its technical indicators over time. Oncopeptides Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Oncopeptides AB. In general, you should focus on analyzing Oncopeptides Stock price patterns and their correlations with different microeconomic environments and drivers.
Oncopeptides Predictive Forecast Models
Oncopeptides' time-series forecasting models is one of many Oncopeptides' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Oncopeptides' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Oncopeptides AB
Checking the ongoing alerts about Oncopeptides for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Oncopeptides AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Oncopeptides AB may become a speculative penny stock | |
| Oncopeptides AB had very high historical volatility over the last 90 days | |
| Oncopeptides AB has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 118.3 M. Net Loss for the year was (1.43 B) with profit before overhead, payroll, taxes, and interest of 74.16 M. | |
| Oncopeptides AB has accumulated about 747.47 M in cash with (1.52 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Additional Tools for Oncopeptides Stock Analysis
When running Oncopeptides' price analysis, check to measure Oncopeptides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncopeptides is operating at the current time. Most of Oncopeptides' value examination focuses on studying past and present price action to predict the probability of Oncopeptides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncopeptides' price. Additionally, you may evaluate how the addition of Oncopeptides to your portfolios can decrease your overall portfolio volatility.